NORTH CHICAGO, Ill. and
CHICAGO, Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE:
ABBV) and the University of Chicago and
have extended their collaboration agreement through 2025 to support
preclinical oncology research.
To date, the collaboration has led to novel insights related to
biomarkers and therapeutic applications for existing AbbVie
programs. This has included the development of novel drug delivery
approaches to enhance anti-tumor immune response and incorporating
unique 3D screening methodologies for selecting novel therapeutic
molecules.
"Our oncology collaboration with the University of Chicago enables us to combine our
expertise in understanding the underlying biology in key areas of
interest, such as immuno-oncology, oncogenic pathways, and
biomarkers of drug sensitivity or disease," said Steve Davidsen, Vice President, Oncology
Discovery Research at AbbVie. "This effort drives towards a common
goal of accelerating discovery efforts and delivering novel
therapies to people living with cancer."
Continuing the intent of the initial research collaboration, the
extension of the collaboration is designed to further accelerate
and advance medical research in oncology at both organizations.
"Our ambition is that the clinical and translational
collaboration between AbbVie and the University of Chicago continues to impact public
health positively," said Kunle
Odunsi, M.D., Ph.D., AbbVie Foundation Director,
University of Chicago Medicine
Comprehensive Cancer Center. "The collaboration has created
valuable opportunities for scientific exchange and the development
of clinical trials for cancer research."
Under the agreement, the organizations will continue working
together to advance research in several areas, focusing on
oncology, and AbbVie gains an option for an exclusive license to
certain University of Chicago
discoveries made as part of the collaboration.
"We look forward to more discoveries together in the years to
come," said Juan de Pablo,
University of Chicago Vice President
for National Laboratories, Science Strategy, Innovation, and Global
Initiatives. "The extension of our agreement will continue to
provide faculty and students with opportunities to work with
colleagues at a global biopharmaceutical leader and translate their
findings from the lab into the real world. It will enable the kind
of preclinical research that is needed to help lay the foundations
for better approaches and treatments with the goal to ultimately
improve quality of life for patients."
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
About the University of
Chicago
The University of Chicago is a
leading academic and research institution that has driven new ways
of thinking since its founding in 1890. As an intellectual
destination, the University draws scholars and students from around
the world to its campuses and centers around the globe. The
University provides a distinctive educational experience and
research environment, empowering individuals to challenge
conventional thinking and pursue field-defining research that
produces new understanding and breakthroughs with global
impact.
About the Polsky Center for Entrepreneurship and Innovation
at the University of Chicago
The Polsky Center for Entrepreneurship and Innovation applies
world-class business expertise from the University of Chicago Booth School of Business to
bring new ideas and breakthrough innovations to market. Home of the
University's technology transfer office, the Polsky
Center's dedicated team of professionals with deep technical
expertise perform market analysis, manage intellectual property,
identify partners, and negotiate partnerships and licenses for
discoveries and inventions developed by faculty, researchers, and
staff. Learn more at polsky.uchicago.edu and follow us on
Twitter @polskycenter.
AbbVie Forward-Looking Statements
Some statements
in this news release are, or may be considered, forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. The words "believe," "expect," "anticipate," "project"
and similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits from AbbVie's acquisition of Allergan plc
("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2020 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
View original
content:https://www.prnewswire.com/news-releases/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical-oncology-research-through-2025-301420540.html
SOURCE AbbVie